{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:02:37Z","timestamp":1795010557928,"version":"4.9.1"},"reference-count":103,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Liposomes nowadays have become a preferential drug delivery system since they provide facilitating\nproperties to drugs, such as improved therapeutic index of encapsulated drug, target and controlled drug delivery, and\nless toxicity. However, conventional liposomes have shown some disadvantages, such as less drug loading capacity,\npoor retention, clearance by kidney or reticuloendothelial system, and less release of hydrophilic drugs. Thus, to\novercome these disadvantages recently, scientists have explored new approaches and methods, viz., ligand conjugation,\npolymer coating, and liposome hybrids, including surface-modified liposomes, biopolymer-incorporated liposomes,\nguest-in-cyclodextrin-in-liposome, liposome-in-hydrogel, liposome-in-film, liposome-in-nanofiber, etc. These\napproaches have been shown to improve the physiochemical and pharmacokinetic properties of encapsulated drugs.\nLately, pharmacokinetic-pharmacodynamic (PK-PD) computational modeling has emerged as a beneficial tool for\nanalyzing the impact of formulation and system-specific factors on the target disposition and therapeutic efficacy of\nliposomal drugs. There has been an increasing number of liposome-based therapeutic drugs, both FDA approved and\nthose undergoing clinical trials, having application in cancer, Alzheimer's, diabetes, and glaucoma. To meet the continuous\ndemand of health sectors and to produce the desired product, it is important to perform pharmacokinetic\nstudies. This review focuses on the physical, physicochemical, and chemical factors of drugs that influence the target\ndelivery of drugs. It also explains various physiological barriers, such as systemic clearance and extravasation. A novel\napproach, liposomal-hybrid complex, an innovative approach as a vesicular drug delivery system to overcome limited\nmembrane permeability and bioavailability, has been discussed in the review. Moreover, this review highlights the\npharmacokinetic considerations and challenges of poorly absorbed drugs along with the applications of a liposomal\ndelivery system in improving PKPD in various diseases, such as cancer, Alzheimer's, diabetes, and glaucoma.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200223666220609141459","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:13:39Z","timestamp":1655100819000},"page":"678-692","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Approaches to Address PK-PD Challenges of Conventional Liposome Formulation\nwith Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update\non Modified Liposomal Drug Delivery System"],"prefix":"10.2174","volume":"23","author":[{"given":"Payal","family":"Kesharwani","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith University, Banasthali, P.O. Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith University, Banasthali, P.O. Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Gururani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith University, Banasthali, P.O. Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith University, Banasthali, P.O. Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banasthali Vidyapith University, Banasthali, P.O. Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","volume":"29","author":"Danhof M.","year":"2008","unstructured":"Danhof M.; de Lange E.C.M.; Della Pasqua O.E.; Ploeger B.A.; Voskuyl R.A.; Mechanism-based Pharmacokinetic-Pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008,29(4),186-191","journal-title":"Trends Pharmacol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","volume":"260","author":"Agrawal M.","year":"2017","unstructured":"Agrawal M.; Ajazuddin; Tripathi, D.K.; Saraf, S.; Saraf, S.; Antimisiaris, S.G.; Mourtas, S.; Hammarlund-Udenaes, M.; Alexander, A. Re-cent advancements in liposomes targeting strategies to cross Blood-Brain Barrier (BBB) for the treatment of Alzheimer\u2019s disease. J Control Release 2017,260,61-77","journal-title":"J Control Release"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijpharm.2010.03.061","volume":"392","author":"Mohanraj V.J.","year":"2010","unstructured":"Mohanraj V.J.; Barnes T.J.; Prestidge C.A.; Silica nanoparticle coated liposomes: A new type of hybrid nanocapsule for proteins. Int J Pharm 2010,392(1-2),285-293","journal-title":"Int J Pharm"},{"key":"ref=4","first-page":"110","volume":"11","author":"He H.","year":"2019","unstructured":"He H.; Yuan D.; Wu Y.; Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regu-lation of liposomal drugs. Pharm 2019,11,110","journal-title":"Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0005-2736(97)00221-6","volume":"1369","author":"Oussoren C.","year":"1998","unstructured":"Oussoren C.; Eling W.M.C.; Crommelin D.J.A.; Storm G.; Zuidema J.; The influence of the route of administration and liposome compo-sition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim Biophys Acta 1998,1369(1),159-172","journal-title":"Biochim Biophys Acta"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/1061186X.2019.1648479","volume":"28","author":"Ero\u011flu \u0130.","year":"2020","unstructured":"Ero\u011flu \u0130.; \u0130brahim M.; Liposome-ligand conjugates: A review on the current state of art. J Drug Target 2020,28(3),225-244","journal-title":"J Drug Target"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.carbpol.2016.09.060","volume":"156","author":"Peng S.","year":"2017","unstructured":"Peng S.; Zou L.; Liu W.; Li Z.; Liu W.; Hu X.; Chen X.; Liu C.; Hybrid liposomes composed of amphiphilic chitosan and phospholipid: Preparation, stability and bioavailability as a carrier for curcumin. Carbohydr Polym 2017,156,322-332","journal-title":"Carbohydr Polym"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.3390\/molecules25235672","volume":"25","author":"Almeida B.","year":"2020","unstructured":"Almeida B.; Nag O.K.; Rogers K.E.; Delehanty J.B.; Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules 2020,25(23),5672","journal-title":"Molecules"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1389450117666160208144143","volume":"19","author":"Jain A.","year":"2018","unstructured":"Jain A.; Jain S.K.; Stimuli-responsive smart liposomes in cancer targeting. Curr Drug Targets 2018,19(3),259-270","journal-title":"Curr Drug Targets"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/1061186X.2017.1367006","volume":"26","author":"Wakaskar R.R.","year":"2018","unstructured":"Wakaskar R.R.; General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target 2018,26(4),311-318","journal-title":"J Drug Target"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.93256","author":"Sharma M.","year":"2020","unstructured":"Sharma M.; Joshi J.; Chouhan N.K.;  In Molecular Pharmacology. 2020"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6591-5_2","volume":"1522","author":"Zhang H.","year":"2017","unstructured":"Zhang H.; Thin-film hydration followed by extrusion method for liposome preparation. Methods Mol Biol 2017,1522,17-22","journal-title":"Methods Mol Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/08982104.2019.1668010","volume":"30","author":"Has C.","year":"2020","unstructured":"Has C.; Sunthar P.; A comprehensive review on recent preparation techniques of liposomes. J Liposome Res 2020,30(4),336-365","journal-title":"J Liposome Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1351\/pac200173081293","volume":"73","author":"Reverchon E.","year":"2001","unstructured":"Reverchon E.; Della Porta G.; Supercritical fluids-assisted micronization techniques. Low-impact routes for particle production. Pure Appl Chem 2001,73(8),1293-1297","journal-title":"Pure Appl Chem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/molecules22071186","volume":"22","author":"Khaw K.Y.","year":"2017","unstructured":"Khaw K.Y.; Parat M.O.; Shaw P.N.; Solvent supercritical fluid technologies to extract bioactive compounds from natural sources: A review. Molecules 2017,22,1186","journal-title":"Molecules"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5650\/jos.ess15192","volume":"65","author":"Yamaguchi S.","year":"2016","unstructured":"Yamaguchi S.; Tsuchiya K.; Sakai K.; Abe M.; Sakai H.; Preparation of nonionic vesicles using the supercritical carbon dioxide reverse phase evaporation method and analysis of their solution properties. J Oleo Sci 2016,65(1),21-26","journal-title":"J Oleo Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.apcbee.2014.01.032","volume":"9","author":"Kumar R.","year":"2014","unstructured":"Kumar R.; Mahalingam H.; Tiwari K.K.; Selection of solvent in supercritical antisolvent process. APCBEE Procedia 2014,9,181-186","journal-title":"APCBEE Procedia"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/2212798410666180925160459","volume":"10","author":"Gomes M.T.M.S.","year":"2019","unstructured":"Gomes M.T.M.S.; Santana \u00c1.L.; Santos D.T.; Meireles M.A.A.; Trends on the rapid expansion of supercritical solutions process applied to food and non-food industries. Recent Pat Food Nutr Agric 2019,10(2),82-92","journal-title":"Recent Pat Food Nutr Agric"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/pr9071162","volume":"9","author":"Trucillo P.","year":"2021","unstructured":"Trucillo P.; Martino M.; Reverchon E.; Supercritical assisted production of lutein-loaded liposomes and modelling of drug release. Process 2021,9,1162","journal-title":"Process"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1021\/la802511a","volume":"25","author":"Meure L.A.","year":"2009","unstructured":"Meure L.A.; Knott R.; Foster N.R.; Dehghani F.; The depressurization of an expanded solution into aqueous media for the bulk production of liposomes. Langmuir 2009,25(1),326-337","journal-title":"Langmuir"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0076-6879(09)65007-2","volume":"465","author":"Yu B.","year":"2009","unstructured":"Yu B.; Lee R.J.; Lee L.J.; Microfluidic methods for production of liposomes. Methods Enzymol 2009,465,129-141","journal-title":"Methods Enzymol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep25876","volume":"6","author":"Carugo D.","year":"2016","unstructured":"Carugo D.; Bottaro E.; Owen J.; Liposome production by microfluidics: Potential and limiting factors. Sci Rep 2016,6,1-15","journal-title":"Sci Rep"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08982104.2012.655285","volume":"22","author":"Song G.","year":"2012","unstructured":"Song G.; Wu H.; Yoshino K.; Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome 2012,22,177-192","journal-title":"J Liposome"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/17512433.2018.1477586","volume":"11","author":"Rodallec A.","year":"2018","unstructured":"Rodallec A.; Fanciullino R.; Lacarelle B.; Ciccolini J.; Seek and destroy: Improving PK\/PD profiles of anticancer agents with nanoparticles. Expert Rev Clin Pharmacol 2018,11(6),599-610","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14728222.6.1.57","volume":"6","author":"Bodey B.","year":"2002","unstructured":"Bodey B.; Neuroendocrine influence on thymic haematopoiesis via the reticulo-epithelial cellular network. Expert Opin Ther Targets 2002,6(1),57-72","journal-title":"Expert Opin Ther Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4103\/1735-5362.213979","volume":"12","author":"Shaker S.","year":"2017","unstructured":"Shaker S.; Gardouh A.R.; Ghorab M.M.; Factors affecting liposomes particle size prepared by ethanol injection method. Res Pharm Sci 2017,12(5),346-352","journal-title":"Res Pharm Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"Danaei M.","year":"2018","unstructured":"Danaei M.; Dehghankhold M.; Ataei S.; Hasanzadeh Davarani F.; Javanmard R.; Dokhani A.; Khorasani S.; Mozafari M.R.; Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018,10(2),57","journal-title":"Pharmaceutics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/03639045.2017.1301948","volume":"43","author":"Li H.","year":"2017","unstructured":"Li H.; Chen Y.; Deng Y.; Wang Y.; Ke X.; Ci T.; Effects of surface charge of low molecular weight heparin-modified cationic liposomes on drug efficacy and toxicity. Drug Dev Ind Pharm 2017,43(7),1163-1172","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s11095-017-2097-3","volume":"34","author":"Kang J.H.","year":"2017","unstructured":"Kang J.H.; Jang W.Y.; Ko Y.T.; The effect of surface charges on the cellular uptake of liposomes investigated by live cell imaging. Pharm Res 2017,34(4),704-717","journal-title":"Pharm Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejps.2017.03.040","volume":"104","author":"Hermann K.F.","year":"2017","unstructured":"Hermann K.F.; Neuhaus C.S.; Micallef V.; Wagner B.; Hatibovic M.; Aschmann H.E.; Paech F.; Alvarez-Sanchez R.; Kr\u00e4mer S.D.; Belli S.; Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intesti-nal permeability. Eur J Pharm Sci 2017,104,150-161","journal-title":"Eur J Pharm Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","volume":"551","author":"Farzaneh H.","year":"2018","unstructured":"Farzaneh H.; Ebrahimi Nik M.; Mashreghi M.; Saberi Z.; Jaafari M.R.; Teymouri M.; A study on the role of cholesterol and phosphati-dylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy. Int J Pharm 2018,551(1-2),300-308","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/C8MD00515J","volume":"10","author":"Nosova A.S.","year":"2019","unstructured":"Nosova A.S.; Koloskova O.O.; Nikonova A.A.; Simonova V.A.; Smirnov V.V.; Kudlay D.; Khaitov M.R.; Diversity of PEGylation methods of liposomes and their influence on RNA delivery. MedChemComm 2019,10(3),369-377","journal-title":"MedChemComm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","volume":"32","author":"Noble G.T.","year":"2014","unstructured":"Noble G.T.; Stefanick J.F.; Ashley J.D.; Kiziltepe T.; Bilgicer B.; Ligand-targeted liposome design: Challenges and fundamental considera-tions. Trends Biotechnol 2014,32(1),32-45","journal-title":"Trends Biotechnol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/ph14030221","volume":"14","author":"Naik H.","year":"2021","unstructured":"Naik H.; Sonju J.J.; Singh S.; Chatzistamou I.; Shrestha L.; Gauthier T.; Jois S.; Lipidated peptidomimetic ligand-functionalized HER2 targeted liposome as nano-carrier designed for doxorubicin delivery in cancer therapy. Pharmaceuticals (Basel) 2021,14(3),221","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e1450","DOI":"10.1002\/wnan.1450","volume":"9","author":"Lee Y.","year":"2017","unstructured":"Lee Y.; Thompson D.H.; Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017,9(5),e1450","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"127871","DOI":"10.1016\/j.bmcl.2021.127871","volume":"39","author":"Veremeeva P.N.","year":"2021","unstructured":"Veremeeva P.N.; Zaborova O.V.; Grishina I.V.; Makeev D.V.; Timoshenko V.A.; Palyulin V.A.; Stimulus-sensitive liposomal delivery system based on new 3,7-diazabicyclo[3.3.1]nonane derivatives. Bioorg Med Chem Lett 2021,39,127871","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=37","first-page":"3623","volume":"9","author":"Wei Y.","year":"2014","unstructured":"Wei Y.; Guo J.; Zheng X.; Wu J.; Zhou Y.; Yu Y.; Ye Y.; Zhang L.; Zhao L.; Preparation, pharmacokinetics and biodistribution of bai-calin-loaded liposomes. Int J Nanomedicine 2014,9,3623-3630","journal-title":"Int J Nanomedicine"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"10061","DOI":"10.2147\/IJN.S216667","volume":"14","author":"Tran B.H.","year":"2019","unstructured":"Tran B.H.; Yu Y.; Chang L.; Tan B.; Jia W.; Xiong Y.; Dai T.; Zhong R.; Zhang W.; Le V.M.; Rose P.; Wang Z.; Mao Y.; Zhu Y.Z.; A Novel liposomal s-propargyl-cysteine: A sustained release of hydrogen sulfide reducing myocardial fibrosis via TGF-\u03b21\/Smad pathway. Int J Nanomedicine 2019,14,10061-10077","journal-title":"Int J Nanomedicine"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/10717544.2013.848247","volume":"21","author":"Huang A.","year":"2014","unstructured":"Huang A.; Su Z.; Li S.; Sun M.; Xiao Y.; Ping Q.; Deng Y.; Oral absorption enhancement of salmon calcitonin by using both N-trimethyl chitosan chloride and oligoarginines-modified liposomes as the carriers. Drug Deliv 2014,21(5),388-396","journal-title":"Drug Deliv"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/08982104.2016.1255640","volume":"28","author":"Klemetsrud T.","year":"2018","unstructured":"Klemetsrud T.; Kj\u00f8niksen A.L.; Hiorth M.; Jacobsen J.; Smistad G.; Polymer coated liposomes for use in the oral cavity - a study of the in vitro toxicity, effect on cell permeability and interaction with mucin. J Liposome Res 2018,28(1),62-73","journal-title":"J Liposome Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.colsurfb.2017.04.061","volume":"156","author":"Smistad G.","year":"2017","unstructured":"Smistad G.; Nystr\u00f6m B.; Zhu K.; Gr\u00f8nvold M.K.; R\u00f8v-Johnsen A.; Hiorth M.; Liposomes coated with hydrophobically modified hy-droxyethyl cellulose: Influence of hydrophobic chain length and degree of modification. Colloids Surf B Biointerfaces 2017,156,79-86","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=42","first-page":"2095","volume":"31","author":"Zeng C.","year":"2018","unstructured":"Zeng C.; Zheng R.; Jiang W.; He C.; Li J.; Xing J.; Chitosan coated chlorogenic acid and rutincomposite phospholipid liposomes: Prepara-tion, characterizations, permeability and pharmacokinetic. Pak J Pharm Sci 2018,31(5)(Suppl.),2095-2102","journal-title":"Pak J Pharm Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijpharm.2014.10.040","volume":"477","author":"Bao Q.Y.","year":"2014","unstructured":"Bao Q.Y.; Zhang N.; Geng D.D.; Xue J.W.; Merritt M.; Zhang C.; Ding Y.; The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles. Int J Pharm 2014,477(1-2),408-415","journal-title":"Int J Pharm"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.nano.2020.102237","volume":"29","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Xie X.; Chen H.; Hou X.; He Y.; Shen J.; Shi J.; Feng N.; Advances in next-generation lipid-polymer hybrid nanocarriers with emphasis on polymer-modified functional liposomes and cell-based-biomimetic nanocarriers for active ingredients and fractions from Chi-nese medicine delivery. Nanomedicine 2020,29,102237","journal-title":"Nanomedicine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/smll.201002180","volume":"7","author":"Katagiri K.","year":"2011","unstructured":"Katagiri K.; Imai Y.; Koumoto K.; Kaiden T.; Kono K.; Aoshima S.; Magnetoresponsive on-demand release of hybrid liposomes formed from Fe3O4 nanoparticles and thermosensitive block copolymers. Small 2011,7(12),1683-1689","journal-title":"Small"},{"key":"ref=46","first-page":"1279","volume":"12","author":"Zhang R.X.","year":"2016","unstructured":"Zhang R.X.; Cai P.; Zhang T.; Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine Nanotechnology. Biol Med (Aligarh) 2016,12,1279-1290","journal-title":"Biol Med (Aligarh)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejpb.2020.07.022","volume":"154","author":"Romana B.","year":"2020","unstructured":"Romana B.; Hassan M.M.; Sonvico F.; Garrastazu Pereira G.; Mason A.F.; Thordarson P.; Bremmell K.E.; Barnes T.J.; Prestidge C.A.; A liposome-micelle-hybrid (LMH) oral delivery system for poorly water-soluble drugs: Enhancing solubilisation and intestinal transport. Eur J Pharm Biopharm 2020,154,338-347","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/polym11060929","volume":"11","author":"G\u00f3mez-Ballesteros M.","year":"2019","unstructured":"G\u00f3mez-Ballesteros M.; L\u00f3pez-Cano J.J.; Bravo-Osuna I.; Herrero-Vanrell R.; Molina-Mart\u00ednez I.T.; Osmoprotectants in hybrid lipo-some\/HPMC systems as potential glaucoma treatment. Polymers (Basel) 2019,11(6),929","journal-title":"Polymers (Basel)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"127296","DOI":"10.1016\/j.cej.2020.127296","volume":"408","author":"Song Y.","year":"2021","unstructured":"Song Y.; Zhang N.; Li Q.; Chen J.; Wang Q.; Yang H.; Tan H.; Gao J.; Dong Z.; Pang Z.; Huang Z.; Qian J.; Ge J.; Biomimetic lipo-somes hybrid with platelet membranes for targeted therapy of atherosclerosis. Chem Eng J 2021,408,127296","journal-title":"Chem Eng J"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"120418","DOI":"10.1016\/j.ijpharm.2021.120418","volume":"599","author":"Liang H.","year":"2021","unstructured":"Liang H.; Zou F.; Liu Q.; Wang B.; Fu L.; Liang X.; Liu J.; Liu Q.; Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. Int J Pharm 2021,599,120418","journal-title":"Int J Pharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.foodhyd.2018.04.040","volume":"83","author":"Zhou F.","year":"2018","unstructured":"Zhou F.; Xu T.; Zhao Y.; Song H.; Zhang L.; Wu X.; Lu B.; Chitosan-coated liposomes as delivery systems for improving the stability and oral bioavailability of acteoside. Food Hydrocoll 2018,83,17-24","journal-title":"Food Hydrocoll"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijpharm.2019.05.007","volume":"565","author":"Caddeo C.","year":"2019","unstructured":"Caddeo C.; Gabriele M.; Fern\u00e0ndez-Busquets X.; Valenti D.; Fadda A.M.; Pucci L.; Manconi M.; Antioxidant activity of quercetin in Eudragit-coated liposomes for intestinal delivery. Int J Pharm 2019,565,64-69","journal-title":"Int J Pharm"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"8434","DOI":"10.1039\/C9CC03571K","volume":"55","author":"Du Y.","year":"2019","unstructured":"Du Y.; He W.; Zhou W.; Li X.; Disulfide phosphatidylcholines: Alternative phospholipids for the preparation of functional liposomes. Chem Commun (Camb) 2019,55(58),8434-8437","journal-title":"Chem Commun (Camb)"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2015.06.023","volume":"213","author":"Kierstead P.H.","year":"2015","unstructured":"Kierstead P.H.; Okochi H.; Venditto V.J.; Chuong T.C.; Kivimae S.; Fr\u00e9chet J.M.J.; Szoka F.C.; The effect of polymer backbone chemis-try on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release 2015,213,1-9","journal-title":"J Control Release"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.colsurfb.2017.11.047","volume":"168","author":"Cuomo F.","year":"2018","unstructured":"Cuomo F.; Cofelice M.; Venditti F.; Ceglie A.; Miguel M.; Lindman B.; Lopez F.; In-vitro digestion of curcumin loaded chitosan-coated liposomes. Colloids Surf B Biointerfaces 2018,168,29-34","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.34172\/apb.2021.074","volume":"11","author":"Bhattacharyya S.","year":"2021","unstructured":"Bhattacharyya S.; Sudheer P.; Das K.; Ray S.; Experimental design supported liposomal aztreonam delivery: In vitro studies. Adv Pharm Bull 2021,11(4),651-662","journal-title":"Adv Pharm Bull"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpharm.2013.07.059","volume":"456","author":"Abu Lila A.S.","year":"2013","unstructured":"Abu Lila A.S.; Nawata K.; Shimizu T.; Ishida T.; Kiwada H.; Use of Polyglycerol (PG), instead of Polyethylene Glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm 2013,456(1),235-242","journal-title":"Int J Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejpb.2018.02.019","volume":"127","author":"Shimizu T.","year":"2018","unstructured":"Shimizu T.; Abu Lila A.S.; Fujita R.; Awata M.; Kawanishi M.; Hashimoto Y.; Okuhira K.; Ishima Y.; Ishida T.; A hydroxyl PEG ver-sion of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Eur J Pharm Biopharm 2018,127,142-149","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/CAD.0000000000000672","volume":"29","author":"Caballero Romero \u00c1.","year":"2018","unstructured":"Caballero Romero \u00c1.; Delgado Ure\u00f1a M.T.; Salmer\u00f3n Garc\u00eda A.; Meg\u00edas Fern\u00e1ndez M.T.; Librada Porri\u00f1o-Bustamante M.; Cabeza Barre-ra, J. Extravasation accidents with liposomal\/liposomal pegylated anthracyclines treated with dexrazoxane: An overview and outcomes. Anticancer Drugs 2018,29(9),821-826","journal-title":"Anticancer Drugs"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/ijms19010195","volume":"19","author":"Riaz M.K.","year":"2018","unstructured":"Riaz M.K.; Riaz M.A.; Zhang X.; Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int J Mol Sci 2018,19,195","journal-title":"Int J Mol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/pharmaceutics12030264","volume":"12","author":"Lee M.K.","year":"2020","unstructured":"Lee M.K.; Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. Pharmaceutics 2020,12(3),264","journal-title":"Pharmaceutics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2217\/nnm-2020-0470","volume":"16","author":"Rachamalla H.K.","year":"2021","unstructured":"Rachamalla H.K.; Bhattacharya S.; Ahmad A.; Sridharan K.; Madamsetty V.S.; Mondal S.K.; Wang E.; Dutta S.K.; Jan B.L.; Jinka S.; Chandra Sekhar Jaggarapu M.M.; Yakati V.; Mukhopadhyay D.; Alkharfy K.M.; Banerjee R.; Enriched pharmacokinetic behavior and an-titumor efficacy of thymoquinone by liposomal delivery. Nanomedicine (Lond) 2021,16(8),641-656","journal-title":"Nanomedicine (Lond)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"112649","DOI":"10.1016\/j.molliq.2020.112649","volume":"303","author":"Singh A.","year":"2020","unstructured":"Singh A.; Neupane Y.R.; Shafi S.; Mangla B.; Kohli K.; PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: In vitro and in vivo assessment. J Mol Liq 2020,303,112649","journal-title":"J Mol Liq"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/10837450.2020.1762645","volume":"25","author":"Zancanella P.","year":"2020","unstructured":"Zancanella P.; Oliveira D.M.L.; de Oliveira B.H.; Woiski T.D.; Pinto C.C.; Santana M.H.A.; Souto E.B.; Severino P.; Mitotane liposomes for potential treatment of adrenal cortical carcinoma: Ex vivo intestinal permeation and in vivo bioavailability. Pharm Dev Technol 2020,25(8),949-961","journal-title":"Pharm Dev Technol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"120346","DOI":"10.1016\/j.ijpharm.2021.120346","volume":"597","author":"d\u2019Avanzo N.","year":"2021","unstructured":"d\u2019Avanzo N.; Torrieri G.; Figueiredo P.; Celia C.; Paolino D.; Correia A.; Moslova K.; Teesalu T.; Fresta M.; Santos H.A.; LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. Int J Pharm 2021,597,120346","journal-title":"Int J Pharm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jconrel.2020.11.013","volume":"330","author":"Zhang H.","year":"2021","unstructured":"Zhang H.; Tang W.L.; Kheirolomoom A.; Fite B.Z.; Wu B.; Lau K.; Baikoghli M.; Raie M.N.; Tumbale S.K.; Foiret J.; Ingham E.S.; Mahakian L.M.; Tam S.M.; Cheng R.H.; Borowsky A.D.; Ferrara K.W.; Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. J Control Release 2021,330,1080-1094","journal-title":"J Control Release"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.12.011","volume":"330","author":"Park Y.I.","year":"2021","unstructured":"Park Y.I.; Kwon S.H.; Lee G.; Motoyama K.; Kim M.W.; Lin M.; Niidome T.; Choi J.H.; Lee R.; pH-sensitive multi-drug liposomes targeting folate receptor \u03b2 for efficient treatment of non-small cell lung cancer. J Control Release 2021,330,1-14","journal-title":"J Control Release"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"111589","DOI":"10.1016\/j.colsurfb.2021.111589","volume":"200","author":"Shahraki N.","year":"2021","unstructured":"Shahraki N.; Mehrabian A.; Amiri-Darban S.; Moosavian S.A.; Jaafari M.R.; Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma. Colloids Surf B Biointerfaces 2021,200,111589","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12951-021-00931-3","volume":"19","author":"Fei W.","year":"2021","unstructured":"Fei W.; Zhao Y.; Wu X.; Sun D.; Yao Y.; Wang F.; Zhang M.; Li C.; Qin J.; Zheng C.; Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy. J Nanobiotechnology 2021,19(1),184","journal-title":"J Nanobiotechnology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.jddst.2021.102351","volume":"62","author":"Haftcheshmeh S.M.","year":"2021","unstructured":"Haftcheshmeh S.M.; Jaafari M.R.; Mashreghi M.; Mehrabian A.; Alavizadeh S.H.; Zamani P.; Zarqi J.; Darvishi M.H.; Gheybi F.; Lipo-somal doxorubicin targeting mitochondria: A novel formulation to enhance anti-tumor effects of Doxil\u00ae in vitro and in vivo. J Drug Deliv Sci Technol 2021,62,102351","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s11671-020-03334-9","volume":"15","author":"Mashreghi M.","year":"2020","unstructured":"Mashreghi M.; Zamani P.; Moosavian S.A.; Jaafari M.R.; Anti-Epcam Aptamer (Syl3c)-Functionalized liposome for targeted delivery of doxorubicin: In vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma. Nanoscale Res Lett 2020,15(1),101","journal-title":"Nanoscale Res Lett"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11596-020-2158-4","volume":"40","author":"Lin Z.","year":"2020","unstructured":"Lin Z.; Ding J.; Sun G.; Application of paclitaxel-loaded EGFR peptide-conjugated magnetic polymeric liposomes for liver cancer therapy. Curr Med Sci 2020,40(1),145-154","journal-title":"Curr Med Sci"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4155\/tde-2020-0070","volume":"11","author":"Narendra Mehata,","year":"2020","unstructured":"Narendra Mehata,; A.K.; Viswanadh, M.K. Formulation and in vitro evaluation of upconversion nanoparticle-loaded liposomes for brain cancer. Ther Deliv 2020,11,557-571","journal-title":"Ther Deliv"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","volume":"394","author":"Rompicherla S.K.L.","year":"2021","unstructured":"Rompicherla S.K.L.; Arumugam K.; Bojja S.L.; Kumar N.; Rao C.M.; Pharmacokinetic and pharmacodynamic evaluation of nasal lipo-some and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 2021,394(8),1737-1755","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.2147\/IJN.S239608","volume":"15","author":"Kong L.","year":"2020","unstructured":"Kong L.; Li X.T.; Ni Y.N.; Xiao H.H.; Yao Y.J.; Wang Y.Y.; Ju R.J.; Li H.Y.; Liu J.J.; Fu M.; Wu Y.T.; Yang J.X.; Cheng L.; Trans-ferrin-modified osthole pegylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice. Int J Nanomedicine 2020,15,2841-2858","journal-title":"Int J Nanomedicine"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/IJN.S283416","volume":"16","author":"Li C.","year":"2021","unstructured":"Li C.; Wan L.; Luo J.; Jiang M.; Wang K.; Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treat-ment. Int J Nanomedicine 2021,16,1261-1280","journal-title":"Int J Nanomedicine"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"126624","DOI":"10.1016\/j.colsurfa.2021.126624","volume":"622","author":"de Souza Von Zuben E.","year":"2021","unstructured":"de Souza Von Zuben E.; Eloy J.O.; Araujo V.H.S.; Gremi\u00e3o M.P.D.; Chorilli M.; Insulin-loaded liposomes functionalized with cell-penetrating peptides: Influence on drug release and permeation through porcine nasal mucosa. Colloids Surf A Physicochem Eng Asp 2021,622,126624","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/21691401.2019.1699812","volume":"48","author":"Villalba A.","year":"2020","unstructured":"Villalba A.; Rodriguez-Fernandez S.; Ampudia R.M.; Cano-Sarabia M.; Perna-Barrull D.; Bertran-Cobo C.; Ehrenberg C.; Maspoch D.; Vives-Pi M.; Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes. Artif Cells Nanomed Biotechnol 2020,48(1),77-83","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/08982104.2020.1780607","volume":"31","author":"Shen H.","year":"2021","unstructured":"Shen H.; Wang W.; Effect of glutathione liposomes on diabetic nephropathy based on oxidative stress and polyol pathway mechanism. J Liposome Res 2021,31(4),317-325","journal-title":"J Liposome Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"111203","DOI":"10.1016\/j.colsurfb.2020.111203","volume":"194","author":"Yazdi J.R.","year":"2020","unstructured":"Yazdi J.R.; Tafaghodi M.; Sadri K.; Mashreghi M.; Nikpoor A.R.; Nikoofal-Sahlabadi S.; Chamani J.; Vakili R.; Moosavian S.A.; Jaafa-ri M.R.; Folate targeted PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies. Colloids Surf B Biointerfaces 2020,194,111203","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1080\/03639045.2017.1353521","volume":"43","author":"Chono S.","year":"2017","unstructured":"Chono S.; Togami K.; Itagaki S.; Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary absorption of encapsu-lated insulin compared with co-administered insulin. Drug Dev Ind Pharm 2017,43(11),1892-1898","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lfs.2019.02.029","volume":"221","author":"Yadav K.S.","year":"2019","unstructured":"Yadav K.S.; Rajpurohit R.; Sharma S.; Glaucoma: Current treatment and impact of advanced drug delivery systems. Life Sci 2019,221,362-376","journal-title":"Life Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijpharm.2018.12.015","volume":"556","author":"Hathout R.M.","year":"2019","unstructured":"Hathout R.M.; Gad H.A.; Abdel-Hafez S.M.; Nasser N.; Khalil N.; Ateyya T.; Amr A.; Yasser N.; Nasr S.; Metwally A.A.; Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication. Int J Pharm 2019,556,192-199","journal-title":"Int J Pharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0378-5173(91)90249-N","volume":"75","author":"Guo L.S.S.","year":"1991","unstructured":"Guo L.S.S.; Fielding R.M.; Lasic D.D.; Hamilton R.L.; Mufson D.; Novel antifungal drug delivery: Stable amphotericin B-cholesteryl sul-fate discs. Int J Pharm 1991,75(1),45-54","journal-title":"Int J Pharm"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/08982109309150729","volume":"3","author":"Adler-Moore J.P.","year":"2008","unstructured":"Adler-Moore J.P.; Proffitt R.T.; Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formula-tion of amphotericin B. J Liposome Res 2008,3(3),429-450","journal-title":"J Liposome Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","volume":"23","author":"Zylberberg C.","year":"2016","unstructured":"Zylberberg C.; Matosevic S.; Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory land-scape. Drug Deliv 2016,23(9),3319-3329","journal-title":"Drug Deliv"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"467429","DOI":"10.1155\/2011\/467429","volume":"2011","author":"Richard B.M.","year":"2011","unstructured":"Richard B.M.; Rickert D.E.; Newton P.E.; Ott L.R.; Haan D.; Brubaker A.N.; Cole P.I.; Ross P.E.; Rebelatto M.C.; Nelson K.G.; Safety evaluation of exparel (depofoam bupivacaine) administered by repeated subcutaneous injection in rabbits and dogs: Species comparison. J Drug Deliv 2011,2011,467429","journal-title":"J Drug Deliv"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/jamp.2008.0686","volume":"21","author":"Li Z.","year":"2008","unstructured":"Li Z.; Zhang Y.; Wurtz W.; Lee J.K.; Malinin V.S.; Durwas-Krishnan S.; Meers P.; Perkins W.R.; Characterization of nebulized liposo-mal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008,21(3),245-254","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics6010001","volume":"6","author":"Puri A.","year":"2013","unstructured":"Puri A.; Phototriggerable liposomes: Current research and future perspectives. Pharmaceutics 2013,6(1),1-25","journal-title":"Pharmaceutics"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/epirev\/mxp008","volume":"31","author":"Vega W.A.","year":"2009","unstructured":"Vega W.A.; Rodriguez M.A.; Gruskin E.; Health disparities in the Latino population. Epidemiol Rev 2009,31(1),99-112","journal-title":"Epidemiol Rev"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0145-2126(03)00092-4","volume":"27","author":"Tomkinson B.","year":"2003","unstructured":"Tomkinson B.; Bendele R.; Giles F.J.; Brown E.; Gray A.; Hart K.; LeRay J.D.; Meyer D.; Pelanne M.; Emerson D.L.; OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leuk Res 2003,27(11),1039-1050","journal-title":"Leuk Res"},{"key":"ref=93","author":"M\u00e9lanie Plourde.","year":"2020","unstructured":"M\u00e9lanie Plourde.; Pharmacokinetic study on three formulations of coenzyme q10 with different carriers - full text view. ClinicalTrials.  gov,  Available from: 2020 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04035525?term=liposomes+to+increase+bioavailability","journal-title":"Available from:"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12050446","volume":"12","author":"Fathalla D.","year":"2020","unstructured":"Fathalla D.; Youssef E.M.K.; Soliman G.M.; Liposomal and ethosomal gels for the topical delivery of anthralin: Preparation, comparative evaluation and clinical assessment in psoriatic patients. Pharmaceutics Epub ahead of print2020,12(5),1","journal-title":"Pharmaceutics"},{"key":"ref=95","year":"2019","unstructured":"Timothy Pardee Vincristine sulfate liposome in treating patients with  relapsed or refractory acute myeloid leukemia - full text view ClinicalTrialsgov,  Available from:\n2019","journal-title":"Timothy Pardee Vincristine sulfate liposome in treating patients with  relapsed or refractory acute myeloid leukemia - full text view ClinicalTrialsgov,"},{"key":"ref=96","author":"Ciudin","unstructured":"Ciudin ;  The use of liposomated iron after bariatric surgery in patients that are receiving parentheral therapy with iron - full text view ClinicalTrialsgov2017 Available from:","journal-title":"The use of liposomated iron after bariatric surgery in patients that are receiving parentheral therapy with iron - full text view ClinicalTrialsgov2017"},{"key":"ref=97","author":"Shira Dinner","unstructured":"Shira Dinner ;  Volasertib and vincristine sulfate liposome in treating patients with relapsed or refractory acute lymphoblastic leukemia Tabu-lar View, ClinicalTrialsgov 2016 Available from:","journal-title":"Volasertib and vincristine sulfate liposome in treating patients with relapsed or refractory acute lymphoblastic leukemia Tabu-lar View, ClinicalTrialsgov 2016"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nou141","volume":"17","author":"Morikawa A.","year":"2015","unstructured":"Morikawa A.; Peereboom D.M.; Thorsheim H.R.; Samala R.; Balyan R.; Murphy C.G.; Lockman P.R.; Simmons A.; Weil R.J.; Tabar V.; Steeg P.S.; Smith Q.R.; Seidman A.D.; Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: A prospective study. Neuro-oncol 2015,17(2),289-295","journal-title":"Neuro-oncol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","volume":"68","author":"Clancy J.P.","year":"2013","unstructured":"Clancy J.P.; Dupont L.; Konstan M.W.; Billings J.; Fustik S.; Goss C.H.; Lymp J.; Minic P.; Quittner A.L.; Rubenstein R.C.; Young K.R.; Saiman L.; Burns J.L.; Govan J.R.; Ramsey B.; Gupta R.; Phase II studies of nebulised Arikace in CF patients with Pseudomonas ae-ruginosa infection. Thorax 2013,68(9),818-825","journal-title":"Thorax"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/bjc.2012.44","volume":"106","author":"Arrieta \u00d3.","year":"2012","unstructured":"Arrieta \u00d3.; Medina L.A.; Estrada-Lobato E.; Hern\u00e1ndez-Pedro N.; Villanueva-Rodr\u00edguez G.; Mart\u00ednez-Barrera L.; Macedo E.O.; L\u00f3pez-Rodr\u00edguez V.; Motola-Kuba D.; Corona-Cruz J.F.; First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with ad-vanced malignant pleural mesothelioma: Phase II trial. Br J Cancer 2012,106(6),1027-1032","journal-title":"Br J Cancer"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-9-308","volume":"9","author":"Beier C.P.","year":"2009","unstructured":"Beier C.P.; Schmid C.; Gorlia T.; Kleinletzenberger C.; Beier D.; Grauer O.; Steinbrecher A.; Hirschmann B.; Brawanski A.; Dietmaier C.; Jauch-Worley T.; K\u00f6lbl O.; Pietsch T.; Proescholdt M.; R\u00fcmmele P.; Muigg A.; Stockhammer G.; Hegi M.; Bogdahn U.; Hau P.; RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer 2009,9(1),308","journal-title":"BMC Cancer"},{"key":"ref=102","author":"Tam P.Y.","year":"2008","unstructured":"Tam P.Y.; Study evaluating inhaled aerolef (liposome-encapsulated  fentanyl)in normal healthy subjects - full text view. clinicaltrials.gov, Available from 2008 https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00708318?cond=NCT00708318","journal-title":"Available from"},{"key":"ref=103","author":"Andr\u00e9s J.","unstructured":"Andr\u00e9s J.;  High-dose sequential chemoimmunotherapy for b-cell lymphomas with central nervous system involvement - Full Text View ClinicalTrialsgov2008 Available from:","journal-title":"High-dose sequential chemoimmunotherapy for b-cell lymphomas with central nervous system involvement - Full Text View ClinicalTrialsgov2008"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220609141459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205800\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220609141459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:19:14Z","timestamp":1692037154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205800\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200223666220609141459","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}